Last reviewed · How we verify

BRV-PV Lot C + DPT-HepB-Hib + OPV

Serum Institute of India Pvt. Ltd. · Phase 3 active Biologic

This is a combination vaccine that provides immunization against rotavirus (BRV-PV), diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, and poliomyelitis through active immune stimulation.

This is a combination vaccine that provides immunization against rotavirus (BRV-PV), diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, and poliomyelitis through active immune stimulation. Used for Prevention of rotavirus gastroenteritis in infants, Prevention of diphtheria, pertussis, and tetanus, Prevention of hepatitis B infection.

At a glance

Generic nameBRV-PV Lot C + DPT-HepB-Hib + OPV
SponsorSerum Institute of India Pvt. Ltd.
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

BRV-PV (Rotavirus vaccine) stimulates immune response against rotavirus antigens to prevent rotavirus gastroenteritis. The DPT-HepB-Hib component provides immunization against diphtheria toxoid, pertussis antigens, tetanus toxoid, hepatitis B surface antigen, and Haemophilus influenzae type b polysaccharide conjugate. OPV (Oral Polio Vaccine) contains live attenuated poliovirus strains that induce mucosal and systemic immunity against poliovirus types 1, 2, and 3.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: